DE60026287T2 - Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 - Google Patents
Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 Download PDFInfo
- Publication number
- DE60026287T2 DE60026287T2 DE60026287T DE60026287T DE60026287T2 DE 60026287 T2 DE60026287 T2 DE 60026287T2 DE 60026287 T DE60026287 T DE 60026287T DE 60026287 T DE60026287 T DE 60026287T DE 60026287 T2 DE60026287 T2 DE 60026287T2
- Authority
- DE
- Germany
- Prior art keywords
- glucose
- patient
- nmr
- lipoprotein
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 77
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 168
- 239000008103 glucose Substances 0.000 claims abstract description 168
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 116
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 116
- 238000001228 spectrum Methods 0.000 claims abstract description 60
- 210000004369 blood Anatomy 0.000 claims abstract description 57
- 239000008280 blood Substances 0.000 claims abstract description 57
- 238000012360 testing method Methods 0.000 claims abstract description 48
- 239000000470 constituent Substances 0.000 claims abstract description 40
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 18
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims abstract description 17
- 210000002381 plasma Anatomy 0.000 claims description 80
- 210000002966 serum Anatomy 0.000 claims description 45
- 206010022489 Insulin Resistance Diseases 0.000 claims description 33
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 32
- 238000004590 computer program Methods 0.000 claims description 21
- 238000010183 spectrum analysis Methods 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 19
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 11
- 238000009826 distribution Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 108010004103 Chylomicrons Proteins 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 238000012502 risk assessment Methods 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 10
- 238000011156 evaluation Methods 0.000 abstract description 4
- 239000013610 patient sample Substances 0.000 abstract description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 81
- 108010007622 LDL Lipoproteins Proteins 0.000 description 28
- 102000007330 LDL Lipoproteins Human genes 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 108010010234 HDL Lipoproteins Proteins 0.000 description 21
- 102000015779 HDL Lipoproteins Human genes 0.000 description 21
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13061299P | 1999-04-22 | 1999-04-22 | |
| US130612P | 1999-04-22 | ||
| PCT/US2000/010463 WO2000065366A1 (en) | 1999-04-22 | 2000-04-19 | Nmr-method for determining the risk of developing type 2 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60026287D1 DE60026287D1 (de) | 2006-04-27 |
| DE60026287T2 true DE60026287T2 (de) | 2006-08-17 |
Family
ID=22445506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60026287T Expired - Lifetime DE60026287T2 (de) | 1999-04-22 | 2000-04-19 | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6518069B1 (enExample) |
| EP (1) | EP1171778B1 (enExample) |
| JP (1) | JP4585693B2 (enExample) |
| AT (1) | ATE319105T1 (enExample) |
| AU (1) | AU4469300A (enExample) |
| CA (1) | CA2367820C (enExample) |
| DE (1) | DE60026287T2 (enExample) |
| ES (1) | ES2256000T3 (enExample) |
| WO (1) | WO2000065366A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259049A1 (de) | 2009-06-02 | 2010-12-08 | Großmann, Kay | Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten |
| DE102014203721A1 (de) * | 2014-02-28 | 2015-09-03 | Bruker Biospin Gmbh | Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
| US20040236673A1 (en) * | 2000-10-17 | 2004-11-25 | Eder Jeff Scott | Collaborative risk transfer system |
| CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
| US7043288B2 (en) | 2002-04-04 | 2006-05-09 | Inlight Solutions, Inc. | Apparatus and method for spectroscopic analysis of tissue to detect diabetes in an individual |
| US20050130321A1 (en) | 2001-04-23 | 2005-06-16 | Nicholson Jeremy K. | Methods for analysis of spectral data and their applications |
| EP1384074A2 (en) * | 2001-04-23 | 2004-01-28 | Metabometrix Limited | Methods for the diagnosis and treatment of bone disorders |
| US20040142403A1 (en) * | 2001-08-13 | 2004-07-22 | Donald Hetzel | Method of screening for disorders of glucose metabolism |
| EP1444526B1 (en) | 2001-11-13 | 2011-09-21 | The Regents of The University of California | Ion mobility analysis of biological particles |
| US6873914B2 (en) | 2001-11-21 | 2005-03-29 | Icoria, Inc. | Methods and systems for analyzing complex biological systems |
| US6862592B1 (en) * | 2001-12-21 | 2005-03-01 | Adobe Systems Incorporated | Document processing in a cross-platform environment |
| EP1329716A1 (en) * | 2002-01-16 | 2003-07-23 | Roche Diagnostics GmbH | Method for screening biological samples for presence of the metabolic syndrome |
| US7730063B2 (en) * | 2002-12-10 | 2010-06-01 | Asset Trust, Inc. | Personalized medicine service |
| US20080027769A1 (en) | 2002-09-09 | 2008-01-31 | Jeff Scott Eder | Knowledge based performance management system |
| US20070011049A1 (en) * | 2005-07-09 | 2007-01-11 | Eder Jeffrey S | Intelligent, personalized commerce chain |
| US7426499B2 (en) * | 2004-11-08 | 2008-09-16 | Asset Trust, Inc. | Search ranking system |
| AU2003285926A1 (en) * | 2002-10-25 | 2004-05-25 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
| US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) * | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| US7197427B2 (en) * | 2004-03-31 | 2007-03-27 | Genworth Financial Inc. | Method for risk based testing |
| EP2189802B1 (en) * | 2004-04-01 | 2014-05-14 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation biosamples |
| US7422224B2 (en) * | 2004-04-13 | 2008-09-09 | Kimir Seatpost | Adjustable bicycle seat post assembly |
| CA3090413C (en) | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
| US7951078B2 (en) * | 2005-02-03 | 2011-05-31 | Maren Theresa Scheuner | Method and apparatus for determining familial risk of disease |
| ATE412364T1 (de) | 2005-03-15 | 2008-11-15 | Hoffmann La Roche | Verfahren und system zur untersuchung des glucosestoffwechsels |
| EP2339346B1 (en) * | 2006-03-24 | 2014-09-03 | Metanomics GmbH | Methods for predicting diabetes type II |
| US8498915B2 (en) * | 2006-04-02 | 2013-07-30 | Asset Reliance, Inc. | Data processing framework for financial services |
| US8247235B2 (en) | 2007-06-08 | 2012-08-21 | Quest Diagnostics Investments Incorporated | Lipoprotein analysis by differential charged-particle mobility |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US9354200B1 (en) | 2008-08-07 | 2016-05-31 | Quest Diagnostics Investments Incorporated | Detection apparatus for differential-charged particle mobility analyzer |
| AU2009308124B2 (en) * | 2008-10-20 | 2014-12-11 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
| US9250211B2 (en) | 2010-12-30 | 2016-02-02 | Quest Diagnostics Investments Incorporated | Magnetic separation of lipoproteins using dextran sulfate |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| WO2012163361A1 (en) * | 2011-05-31 | 2012-12-06 | Aarhus Universitet | Method and system for identification of physiological imbalance in an animal |
| US9689942B2 (en) | 2011-06-30 | 2017-06-27 | Liposcience, Inc. | Quantitative NMR clinical analyzers with automatic NMR temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
| US20150260631A1 (en) * | 2014-03-17 | 2015-09-17 | Health Diagnostic Laboratory, Inc. | System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions |
| EP3210028A1 (en) | 2014-10-21 | 2017-08-30 | True Health IP LLC | Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer |
| US20160109472A1 (en) | 2014-10-21 | 2016-04-21 | Health Diagnostic Laboratory, Inc. | Quantitative molar concentration detection of specific apolipoprotein-containing particles present in bodily fluids by using capillary electrophoresis |
| US10330690B2 (en) | 2014-10-27 | 2019-06-25 | Helena Laboratories Corporation | Lp(a) subform size identification by capillary isotachophoresis electrophoresis with laser-induced-fluorescence |
| JP2017537926A (ja) | 2014-12-04 | 2017-12-21 | ノバルティス アーゲー | Ｋｌｏｔｈｏ変種ポリペプチドを使用する方法および組成物 |
| CN118818069A (zh) | 2017-09-07 | 2024-10-22 | 力保科学公司 | 多参数代谢脆弱性指数评估 |
| US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
| WO2023239869A1 (en) * | 2022-06-09 | 2023-12-14 | Quest Diagnostics Investments Llc | Quantification of lipoprotein subfractions by ion mobility |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US4933844A (en) * | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| JPH06505089A (ja) | 1989-12-21 | 1994-06-09 | ザ ベス イスラエル ホスピタル アソシエイション | アテローム性動脈硬化症のリスク予知法 |
| AU2384292A (en) | 1991-07-30 | 1993-03-02 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| US5585235A (en) * | 1993-04-13 | 1996-12-17 | Diagnescent Technologies, Inc. | Fluorescent assay and method that corrects for spectral interference |
| NZ275054A (en) * | 1993-11-08 | 1997-04-24 | Peptide Delivery Systems Pty L | Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein |
| US5685300A (en) | 1994-04-01 | 1997-11-11 | Kuenstner; J. Todd | Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy |
| US6163154A (en) | 1997-12-23 | 2000-12-19 | Magnetic Diagnostics, Inc. | Small scale NMR spectroscopic apparatus and method |
| US6226082B1 (en) | 1998-06-25 | 2001-05-01 | Amira Medical | Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy |
-
2000
- 2000-04-19 US US09/550,359 patent/US6518069B1/en not_active Expired - Lifetime
- 2000-04-19 CA CA002367820A patent/CA2367820C/en not_active Expired - Fee Related
- 2000-04-19 AT AT00926111T patent/ATE319105T1/de not_active IP Right Cessation
- 2000-04-19 DE DE60026287T patent/DE60026287T2/de not_active Expired - Lifetime
- 2000-04-19 JP JP2000614054A patent/JP4585693B2/ja not_active Expired - Fee Related
- 2000-04-19 AU AU44693/00A patent/AU4469300A/en not_active Abandoned
- 2000-04-19 EP EP00926111A patent/EP1171778B1/en not_active Expired - Lifetime
- 2000-04-19 WO PCT/US2000/010463 patent/WO2000065366A1/en not_active Ceased
- 2000-04-19 ES ES00926111T patent/ES2256000T3/es not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259049A1 (de) | 2009-06-02 | 2010-12-08 | Großmann, Kay | Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten |
| DE102009026651A1 (de) | 2009-06-02 | 2011-02-17 | Großmann, Kay, Dr. rer. nat. (Chemie) | Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten |
| DE102014203721A1 (de) * | 2014-02-28 | 2015-09-03 | Bruker Biospin Gmbh | Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe |
| DE102014203721B4 (de) | 2014-02-28 | 2018-12-27 | Bruker Biospin Gmbh | Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000065366A8 (en) | 2001-03-29 |
| JP2002543392A (ja) | 2002-12-17 |
| US6518069B1 (en) | 2003-02-11 |
| AU4469300A (en) | 2000-11-10 |
| WO2000065366A1 (en) | 2000-11-02 |
| CA2367820C (en) | 2009-12-22 |
| JP4585693B2 (ja) | 2010-11-24 |
| CA2367820A1 (en) | 2000-11-02 |
| ES2256000T3 (es) | 2006-07-16 |
| EP1171778B1 (en) | 2006-03-01 |
| EP1171778A1 (en) | 2002-01-16 |
| DE60026287D1 (de) | 2006-04-27 |
| ATE319105T1 (de) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026287T2 (de) | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 | |
| DE102010038014B4 (de) | Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung | |
| DE68916729T2 (de) | Lipoprotein-Analyse in Blut mittels magnetischer Kernresonanz. | |
| Ranganath et al. | Dissociable correlates of recollection and familiarity within the medial temporal lobes | |
| Chard et al. | Brain metabolite changes in cortical grey and normal‐appearing white matter in clinically early relapsing–remitting multiple sclerosis | |
| DE60114036T2 (de) | Verfahren zur charakterisierung von spektrometern | |
| DE69821475T2 (de) | Verwendung von eindimensionaler kernspinresonanz fur identifizierung von liganden fur ziel-biomolekule | |
| EP2997365B1 (de) | Analyseverfahren zur klassifikationsunterstützung | |
| DE69905310T2 (de) | Reflexalgorithmus zur frühen und kostengünstigen Diagnose von myokardischen Infarkten geeignet für automatisierte diagnostische Plattformen | |
| DE60028005T2 (de) | Verfahren für die qualitätskontrolle und standardisierung von medizinischen pflanzenprodukten | |
| DE102004026903B4 (de) | Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür | |
| DE60308864T2 (de) | Verfahren der Resonanz-Spektroskopie für die Analyse von statistischen Eigenschaften von Proben | |
| DE102005021401A1 (de) | Verfahren und System zur Feststellung und Überwachung von neurodegenerativen Erkrankungen unter Verwendung von Magnetresonanzspektroskopie | |
| Stein et al. | Characterization of the distribution of spin–lattice relaxation rates of lipid spin labels in fiber cell plasma membranes of eye lenses with a stretched exponential function | |
| EP1522847B1 (de) | Analytisches Verfahren zum Bestimmen von kristallographischen Phasen einer Messprobe | |
| DE60130020T2 (de) | Computerisierte identifizierung normaler und abnormaler diurnaler cortisolsekretionsmuster und von testosteronspiegeln aus menschlichen speichelproben | |
| DE20023042U1 (de) | Vorrichtung zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie | |
| DE69633681T2 (de) | Verfahren zur feststellung von reperfusion nach thrombolytischer therapie | |
| DE3788812T2 (de) | Verfahren zum Nachweis von Krebs durch Anwendung von kernmagnetischer Resonanz. | |
| DE60028374T2 (de) | Verfahren und apparatur zum präsentieren von daten von thrombose- und haemostaseassays | |
| DE60008159T2 (de) | Trenn- und Analyseverfahren für Lipoproteine, Vorrichtung zur Durchführung desselben, sowie ein die Vorrichtung enthaltendes System | |
| EP3413053B1 (de) | Kalibration von lupus antikoagulans | |
| DE69906865T2 (de) | Automatisches Diagnosesystem zur Durchführung von Immunoassays und klinisch-chemischen Assays nach einem Reflexalgorithmus | |
| JP2006505789A (ja) | 脱髄の検出 | |
| EP3772659B1 (de) | Partialvolumenanalyse für magnetresonanzfingerprinting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |